Life-threatening peanut reactions among children have become ‘almost epidemic’, an expert has warned.
Dr Scott Sicherer, director of the Jaffe Food Allergy Institute at New York’s Mount Sinai hospital, said the rise in cases is impossible to deny.
Peanut allergies have tripled from affecting one in 250 children to just one in 70 between 1997 and 2008, a study by the institute found.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.